Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;38(7):1452-7.
doi: 10.3899/jrheum.110271.

Patient-reported outcomes in chronic gout: a report from OMERACT 10

Jasvinder A Singh  1 , Will J Taylor, Lee S Simon, Puja P Khanna, Lisa K Stamp, Fiona M McQueen, Tuhina Neogi, Angelo L Gaffo, Michael A Becker, Patricia A MacDonald, Omar Dabbous, Vibeke Strand, Nicola D Dalbeth, Daniel Aletaha, N Lawrence Edwards, H Ralph Schumacher Jr
Affiliations

Patient-reported outcomes in chronic gout: a report from OMERACT 10

Jasvinder A Singh et al. J Rheumatol. 2011 Jul.

Abstract

Objective: To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).

Methods: During the OMERACT 10 gout workshop, validation data were presented for key PRO domains including pain [pain by visual analog scale (VAS)], patient global (patient global VAS), activity limitation [Health Assessment Questionnaire-Disability Index (HAQ-DI)], and a disease-specific measure, the Gout Assessment Questionnaire version 2.0 (GAQ v2.0). Data were presented on all 3 aspects of the OMERACT filters of truth, discrimination, and feasibility. One PRO, health-related quality of life measurement with the Medical Outcomes Study Short-form 36 (SF-36), was previously endorsed at OMERACT 9.

Results: One measure for each of the 3 PRO of pain, patient global, and activity limitation was endorsed by > 70% of the OMERACT delegates to have appropriate validation data. Specifically, pain measurement by VAS was endorsed by 85%, patient global assessment by VAS by 73%, and activity limitation by HAQ-DI by 71%. GAQ v2.0 received 30% vote and was not endorsed due to several concerns including low internal consistency and lack of familiarity with the measure. More validation studies are needed for this measure.

Conclusion: With the endorsement of one measure each for pain, patient global, SF-36, and activity limitation, all 4 PRO for chronic gout have been endorsed. Future validation studies are needed for the disease-specific measure, GAQ v2.0. Validation for PRO for acute gout will be the focus of the next validation exercise for the OMERACT gout group.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcome measures in chronic gout. Key domains for chronic gout as endorsed in 2008 at OMERACT 9. HRQOL: health-related quality of life.
Figure 2
Figure 2
Measures for pain and patient global assessment used in 2 RCT of pegloticase.
See this image and copyright information in PMC

References

    1. U.S. Department of Health and Human Services. Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to support labeling claims. Rockville, Maryland: [Accessed 15 March 2011]. 2009. Guidance for Industry. Internet. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati.... - PubMed
    1. NIH. Patient-Reported Outcomes Measurement Information System: dynamic tools to measure health outcomes from the patient perspective. National Institutes of Health; [Accessed March 15, 2011]. PROMIS. Internet. Available from: http://www.nihpromis.org/default.aspx.
    1. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15:3–7. - PubMed
    1. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. Value Health. 2007;10:231–7. - PubMed
    1. Krishnan E. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008;10:249–55. - PubMed

Publication types

Substances